Portal de Periódicos da CAPES

SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia

2020; Elsevier BV; Volume: 306; Linguagem: Inglês

10.1016/j.atherosclerosis.2020.06.011

1879-1484

Antonio Gallo, Sybil Charriere, Alexandre Vimont, M. John Chapman, Denis Angoulvant, Franck Boccara, Bertrand Cariou, Valérie Carreau, Alain Carrié, Éric Bruckert, Sophie Béliard, Denis Angoulvant, Sophie Béliard, Franck Boccara, Éric Bruckert, Bertrand Cariou, Valérie Carreau, Alain Carrié, Sybil Charriere, Yves Cottin, Mathilde Di Filippo, Sonia Dulong, Vincent Durlach, Michel Farnier, Émile Ferrari, Dorota Ferrieres, Jean Ferrieres, Antonio Gallo, Philippe Giral, Sophie Gonbert, R. Hankard, Jocelyn Inamo, Olga Kalmykova, Michel Krempf, Philippe Moulin, François Paillard, Noël Peretti, Agnès Perrin‐Guyomard, Jean‐Pierre Rabès, Ariane Sultan, Patrick Tounian, René Valéro, Bruno Vergès, Cecile Yelnik, Olivier Ziegler,

Cancer, Lipids, and Metabolism

Background and aims Patients with heterozygous familial hypercholesterolemia (HeFH) present elevated cardiovascular (CV) risk. Current CV risk stratification algorithms developed for the general population are not adapted for heFH patients. It is therefore of singular importance to develop and validate CV prediction tools, which are dedicated to the HeFH population. Methods Our first objective was to validate the Spanish SAFEHEART-risk equation (RE) in the French HeFH cohort (REFERCHOL), and the second to compare SAFEHEART-RE with the low-density-lipoprotein-cholesterol (LDL-C)-year-score for the prediction of CV events in the HeFH French population. Results We included HeFH (n = 1473) patients with a genetic or clinical diagnosis (DLCN score ≥8). Among them, 512 patients with a 5-year follow-up were included to validate the 5 year-CV-RE. A total of 152 events (10.3%) occurred in the entire population of 1473 patients during a mean follow-up of 3.9 years. Over the five-year follow-up, non-fatal CV events occurred in 103 patients (20.2%). Almost all the parameters used in the SAFEHEART-RE were confirmed as strong predictors of CV events in the REFERCHOL cohort. The C-statistic revealed a satisfactory performance of both the SAFEHEART-RE and LDL-C-year-scores in predicting CV events for all the patients (primary and secondary prevention) (C-index 0.77 and 0.70, respectively) as well as for those in primary prevention at inclusion (C-index 0.78 and 0.77, respectively). Conclusions This analysis represents the first external validation of the SAFEHEART-RE and demonstrated that both SAFEHEART-RE and the LDL-C-year-score are good predictors of CV events in primary prevention HeFH patients.